FDA's top can­cer lead­ers want to shift how com­pan­ion di­ag­nos­tics are reg­u­lat­ed

The FDA is rec­og­niz­ing a ma­jor dis­con­nect for some new can­cer drugs. This idea that each new on­col­o­gy drug ap­proved is aligned at the time of ap­proval with one di­ag­nos­tic test to se­lect pa­tients for the safe and ef­fec­tive use of the treat­ment is not what’s hap­pen­ing, “prac­ti­cal­ly speak­ing,” says Harpreet Singh, di­vi­sion di­rec­tor at FDA’s On­col­o­gy Cen­ter for Ex­cel­lence (OCE).

In­stead, in the re­al world, “mul­ti­ple lo­cal­ly-de­vel­oped tests are be­ing used” to en­roll pa­tients in tri­als, and those tests are large­ly un­reg­u­lat­ed. So by the time the clin­i­cal da­ta ar­rives at FDA, she said, “of­ten we do not have the ap­pro­pri­ate, and the amount of pa­tient sam­ples to bridge all of the lo­cal tests that were used to this one cen­tral di­ag­nos­tic test.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER